Research Paper Advance Articles
Precision prognostication in breast cancer: unveiling a long non-coding RNA-based model linked to disulfidptosis for tailored immunotherapeutic strategies
Figure 6. The capacity of the DAL model to forecast survival variations in high and low-risk groups among distinct clinical subgroups. (A, B) age (>50 and ≤50 years), (C, D) gender, (E, F) M stage, (G, H) N stage, (I, J) clinical stage, and (K, L) T stage.